摘要Prostate cancer is a leading cause of cancer-related death in men worldwide.Luteinizing hormone-releasing hormone receptor(LHRH-R)agonists and antagonists are known to achieve castration-level testosterone suppression;however,long-term data comparing the survival benefits of these therapies are insufficient to inform treatment decisions.Furthermore,the advent of next-generation hormonal agents(NHAs),such as abiraterone and enzalutamide,have shifted the paradigm of managing prostate cancer.Although LHRH-R agonists and antagonists remain the cornerstone treatment across various stages of prostate cancer,they are increasingly administered with NHAs,because the combination treatment confers a survival advantage.Nevertheless,the differences in efficacy and safety profiles among various combinations of LHRH-R agonists and antagonists and NHAs remain unclear.Hence,this narrative review is aimed at providing a comprehensive overview of the long-term outcomes of various LHRH-R agonists and antagonists.Key data from major clinical studies are summarized,categorized by disease stage.LHRH-R agonists and antagonists,particularly goserelin,have demonstrated long-term survival benefits in patients with localized and locally advanced prostate cancer.The clinical outcomes of different LHRH-R agonists and antagonists in combination with NHAs have also been evaluated.Among the various combinations,goserelin plus abiraterone appears to have a manageable safety profile with relatively low rates of hot flushes and fatigue.Overall,long-term survival data and safety profiles should be considered in selecting optimal combination therapies for prostate cancer treatment.